VYGR compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

VYGRVoyager Therapeutics, Inc.

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

VYGRVoyager Therapeutics, Inc.

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

VYGR: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only VYGR 2

NBIXNeurocrine Biosciencescustomer

NVSNovartis Pharmacustomer

Shared 0

No shared counterparties.

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

Role chip = supplier or customerSource: SEC EDGAR

8 more · AMGN chain ›

Price

rebased to 0%

VYGR, solidAMGN, dashed

VYGRVoyager Therapeutics, Inc.

1.87· pre 1.88· delayed

Mkt cap$115.2MRevenue$3MQ2 FY26Revenue$40MFY25

AMGNAmgen Inc

478.34· pre 479.89· delayed

Pre-marketNov 5 '26delayed

Mkt cap$258.8BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

Compare

Pre-marketNov 5 '26delayed

VYGRVoyager Therapeutics, Inc.

AMGNAmgen Inc

1.87pre 1.88delayed

Price

478.34pre 479.89delayed

$115.2M

Mkt cap

$258.8B

Q2 FY26$3M

Revenue

$10.4BQ3 FY26

FY25$40M

Revenue

$36.8BFY25

VYGR1.87vsAMGN478.34Pre-marketNov 5 '26delayed